© Copyright Acquisition International 2024 - All Rights Reserved.

Article Image - Prima BioMed Acquisition of Immutep SA
Posted 30th January 2015

Prima BioMed Acquisition of Immutep SA

Marc Voigt is CEO of Prima BioMed Ltd. He talks to AI Global about a landmark transaction, completed earlier this year.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Prima BioMed Acquisition of Immutep SA

Prima BioMed Acquisition of Immutep SA

Marc Voigt is CEO of Prima BioMed Ltd. He talks to AI Global about a landmark transaction, completed earlier this year.

Prima BioMed Ltd (Prima) is a biotechnology company in the field of cancer immunotherapy. It is listed on the Australian Stock Exchange, NASDAQ in the US and the Deutsche Börse in Germany.

 Marc Voigt tells us more about the firm and how it differentiates from the competition. “We specialise in cell therapy manufacturing of autologous blood products and are conducting Phase II clinical trials in ovarian and pancreatic cancer with our lead product CVac™,” he begins. “Through the acquisition of Immutep we also now have a portfolio of products relating to the LAG-3 immune control mechanism of T cells. Products include an immune activator called IMP321 and 2 antibodies licensed to development partners GSK and Novartis.

 “Our differentiating feature is a pipeline focused on multiple immunotherapy products capable of development individually, or in combination, with other immunotherapy treatments creating a flexible product development pathway.”

 Earlier this year Prima announced the acquisition of French private biotechnology company Immutep SA in early October which was completed in late November 2014. 

 Prima paid an upfront cash payment of US$10.8M and issued US$3m worth of Prima BioMed ordinary shares to Immutep shareholders, as well as 200M warrants of which 30M are dependent on a milestone. The remaining cash component of US$7.2M is payable, subject to the achievement of milestones related to Immutep’s acquired product portfolio and warranty retention arrangements.

Voigt explains the strategic rationale behind the deal and what it will achieve for the parties involved. “The aim of the transaction was to create shareholder value and build up critical mass with cutting edge technology. Further strengthening our scientific management team and establishing a pipeline of complimentary products that can be developed in parallel or in combination with other therapies to create an optimal anti-cancer response were of primary strategic importance. The combined entity will have significantly enhanced access to scientific, manufacturing and clinical expertise; and there will be potential revenues from near, mid and long-term milestones from partnerships for each of its products. Furthermore, research and development will continue to create new product opportunities and cost savings via merging internal administrative activities.

 “The acquisition will give Prima far greater growth opportunities making it easier to partner technologies and raise further capital. A diverse product pipeline will make us far more attractive than when we were focused solely on a single product.

 “The deal will provide increased visibility for Prima in the cancer immunotherapy field. The LAG-3 technology is in a high profile immune checkpoint inhibitor space that is being favoured by larger pharmaceutical companies and the medical community. The growth of the industry and the interest in these molecules should help drive partnering opportunities.

 “It is anticipated the merged entity will generate a pipeline of products that might also be supported financially by access to global grant funding opportunities.  The partnerships of the combined entity and the diverse mechanisms of action of the products being created will increase the likelihood of successfully commercialising beneficial cancer treatments.”

 The deal will allow Immutep to gain access to greater capital market opportunities via Prima’s triple listing on the ASX, NASDAQ and Deutsche Borse to generate the further investment needed to support the growth of its product portfolio. For Immutep’s venture capital shareholders the transaction provided an exit opportunity.  Voigt elaborates: “The Immutep personnel will also gain access to Prima’s scientific and clinical advisory boards and expertise from the clinical, manufacturing and business development teams. This will help guide the optimal development of the LAG-3 technologies both technically and commercially.

 “Prima gains access to a new pipeline of products in a high profile area that has already been partnered. Development is at partners cost in some cases so investment risk is reduced if there is technical failure. Prima also gains internal R&D capability with laboratory space in Paris and scientific expertise from Immutep staff. Potential milestone payments from partners add potential revenues and the partnerships provide access to relationships with larger pharmaceutical companies for future projects.”

 The deal process was relatively straight forward, as Voigt continues: “Discussions commenced in January 2014. Immutep’s founders provided early due diligence material for revision by the Prima clinical, manufacturing, intellectual property and business development teams. Upon negotiation of a non-binding term sheet, a full-fledged due diligence proceeded via thorough review of an electronic data room that included corporate information. Independent advice was provided by legal, clinical and financial advisors.

“In order to mitigate potential financing risk, a structured finance arrangement was negotiated with Bergen Global Opportunity Fund LLC to provide funds of up to US$37.4M over two years. Flexible terms for the financing were agreed with an ability to pause or terminate tranches of funding to minimise shareholder dilution. 

“The binding terms of a Share Sale Agreement with Immutep were agreed and announced on the 2 October together with the Bergen Funding Agreement.  Independent valuations on the Immutep transaction were performed by KPMG, Australia and Maxim Group LLC., New York, USA.”

“Given the potential of the Immutep products the whole process has been intense. After signing the LOI the main challenge was completing the due diligence, negotiating terms and securing the funding agreement within tight timeframes.

 “With staff and consultants engaged across three continents/time zones and some language differences as well, the deal negotiations coordination was sometimes a challenge. Most staff and consultants were incredibly flexible, working very long hours to hold multiple teleconferences.”

 Voigt describes how the current business climate is conducive to a problem-free transaction. “The current business climate is generally favouring merger and acquisition activity. The available opportunities to consider were therefore perhaps more limited as many technologies have been acquired by larger companies with greater resources.”

 Voigt’s predictions for the future of the parties involved are very positive. “We will continue to develop these programs in clinical trials and continue to be active in business development, thus creating a win-win situation for all parties involved.”



Categories: M&A

You Might Also Like
Read Full PostRead - Eye Icon
EXPEN International Tech Transactions Advisory of the Year 2017
01/08/2017EXPEN International Tech Transactions Advisory of the Year 2017

EXPEN International Tech Transactions Advisory of the Year 2017

Read Full PostRead - Eye Icon
Tips for Students: Leadership Qualities That Are Important to Business
04/09/2020Tips for Students: Leadership Qualities That Are Important to Business

You might have heard the saying that a leader can’t be created, they are only born that way. This can’t be further from the truth as almost everyone can become a leader.

Read Full PostRead - Eye Icon
The Crucial Role of Custom Store Signs in Small Business Success
03/07/2023The Crucial Role of Custom Store Signs in Small Business Success

In the cutthroat world of commerce, standing out and winning over clients can be a real struggle for small businesses. Custom store signs are a powerful instrument that can make a big difference. They’re often the initial touchpoint with potential custom

Read Full PostRead - Eye Icon
Hillarys transforms contact centre operations with IPI
08/10/2019Hillarys transforms contact centre operations with IPI

Contact centre enhancements save £500K in first year, reduce attrition rates, boost customer experience and employee engagement as part of programme of digital transformation.

Read Full PostRead - Eye Icon
Should I Switch to a New Payroll Provider Mid-Year?
30/09/2021Should I Switch to a New Payroll Provider Mid-Year?

Business owners (regardless of size) are not fond of change. That’s because change usually comes in the same package with new investments and disruption of activity. However, when it’s needed for the improvement of your business process and a better future

Read Full PostRead - Eye Icon
Makesworth: More Than Just Accountants
24/05/2018Makesworth: More Than Just Accountants

Makesworth Accountants is a leading firm of Chartered Certified Accountants located in Harrow.

Read Full PostRead - Eye Icon
Applied Software Acquires Tekni
22/02/2016Applied Software Acquires Tekni

Applied Software®, a systems integrator to the AEC, Construction and Manufacturing industries, announced today the acquisition of Tekni, a reseller of Autodesk software for the manufacturing marketplace headquartered in Chesterfield, Missouri.

Read Full PostRead - Eye Icon
How to Drive More Foot Traffic to Your Business
01/03/2024How to Drive More Foot Traffic to Your Business

For your small business to thrive, you need to make sure it’s fed with interested customers each day. The more people you lead to your doors, the better your revenue numbers get. That’s because foot traffic includes customers who are either curious

Read Full PostRead - Eye Icon
Ethical Leadership: The Cornerstone of Trust in Managerial Roles
18/03/2024Ethical Leadership: The Cornerstone of Trust in Managerial Roles

Nowadays, ethical leadership has become more than simply a catchphrase; it is the cornerstone around which any organizational structure is based. Prioritizing moral behavior and judgment as a manager has a snowball effect that improves team relationships, upho

Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.